Valuation : GlucoTrack, Inc.

Market Cap 1.31M 1.13M 1.06M 967K 1.81M 125M 1.82M 12.58M 4.86M 63.52M 4.92M 4.81M 201M P/E 2024 *
-
P/E 2025 -0.12x
Enterprise Value -2.63M -2.26M -2.13M -1.94M -3.63M -250M -3.64M -25.22M -9.75M -127M -9.86M -9.65M -403M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
89.82%
Yield 2024 *
-
Yield 2025 -
1 day-1.46%
1 week-6.80%
Current month-27.20%
1 month-48.80%
3 months-48.56%
6 months-85.27%
Current year-94.67%
1 week 2.9
Extreme 2.9
3.31
1 month 2.9
Extreme 2.9
6.3
Current year 2.9
Extreme 2.9
63.6
1 year 2.9
Extreme 2.9
212.1
3 years 2.9
Extreme 2.9
89,100.09
5 years 2.9
Extreme 2.9
585,000.58
10 years 2.9
Extreme 2.9
7,020,007.02
Manager TitleAgeSince
Chief Executive Officer 55 2026-07-13
Director of Finance/CFO 66 2025-01-27
Chief Operating Officer - 2025-01-31
Director TitleAgeSince
Director/Board Member 59 2024-08-26
Director/Board Member 56 2023-08-24
Chairman 64 2024-02-12
Date Insider Type Main position Quantity % Market Cap. Importance
3/26/25 Free

Director

4,490 0.0431%
3/25/25 Free

Director

8,747 0.0840%
3/25/25 Free

Director

5,473 0.0526%
Change 5-day change 1-year change 3-year change Capi.($)
+2.87%-6.80%-95.54%-99.99% 1.31M
+0.32%-6.94%-2.69%+11.17% 46.38B
-1.47%-2.07%+410.49%+528.22% 44.51B
-1.30%-6.05%+38.79%+18.51% 42.3B
-2.20%-5.25%+9.46%+64.23% 39.91B
0.00%-1.72%+13.42%+42.33% 32.79B
-0.18%-3.54% - - 17.13B
-1.10%-1.82%+22.22%+108.55% 16.36B
+0.31%-3.43%+12.71%+30.93% 14.31B
-2.04%-6.54%+78.88%+37.32% 13.29B
Average -0.90%-3.70%+54.19%+82.36% 26.7B
Weighted average by Cap. -0.89%-3.04%+88.85%+125.99%

Financials

2024 2025
Net sales - -
Net income -22.6M -19.44M -18.31M -16.68M -31.21M -2.15B -31.34M -217M -83.87M -1.1B -84.85M -83.01M -3.47B -19.39M -16.68M -15.71M -14.31M -26.78M -1.84B -26.89M -186M -71.96M -940M -72.8M -71.22M -2.98B
Net Debt -5.35M -4.6M -4.33M -3.95M -7.39M -509M -7.42M -51.37M -19.86M -259M -20.09M -19.65M -822M -3.94M -3.39M -3.19M -2.91M -5.44M -375M -5.46M -37.81M -14.61M -191M -14.78M -14.46M -605M
Logo GlucoTrack, Inc.
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Employees
15
Date Price Change Volume
26-09-10 US$3.136 -0.13% 5,082
26-09-09 US$3.140 +7.17% 59,005
26-09-08 US$2.930 -1.68% 36,078
26-09-04 US$2.980 -10.24% 74,999
26-09-03 US$3.320 -5.95% 47,710
  1. Stock Market
  2. Stocks
  3. GCTK Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!